GlassScriptPhysician profile
Taylor Brooke Saskin
NPI 1134906050
$7,743.62
in general payments reported to CMS, 2019-2025
29 companies · $3,260 in 2025
The $3,260 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $249 · 2024: $4,234 · 2025: $3,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,584 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,583.63 |
| Education | $159.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $993.71 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $901.53 | 2024-2025 | |
| Axsome Therapeutics, INC. | $632.55 | 2023-2025 | Auvelity, Symbravo |
| Pfizer INC. | $623.75 | 2023-2025 | |
| Amgen INC. | $615.41 | 2023-2025 | Otezla, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $514.76 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $507.95 | 2023-2025 | Zepbound, Mounjaro, Kisunla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $342.73 | 2023-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $301.95 | 2023-2025 | |
| Astellas Pharma US INC | $285.00 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.83 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $205.56 | 2024-2025 | Verquvo, Gardasil 9, Capvaxive |
| Novo Nordisk INC | $197.08 | 2024-2025 | Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $195.70 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $194.81 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $142.83 | 2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $141.41 | 2024 | Quviviq |
| Dermavant Sciences, INC. | $120.22 | 2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $118.32 | 2024-2025 | |
| Exact Sciences Corporation | $117.50 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Verona Pharma, INC. | $76.56 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $55.33 | 2023-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.75 | 2024-2025 | Jardiance |
| Lundbeck LLC | $48.92 | 2024-2025 | Rexulti |
| Grifols USA, LLC | $22.12 | 2024 | Xembify |
| Almatica Pharma LLC | $20.07 | 2025 | Loreev Xr |
| Seqirus USA INC | $19.15 | 2024 | Flucelvax, Fluad |
| Biogen, INC. | $16.75 | 2024 | Skyclarys |
| Phathom Pharmaceuticals, INC. | $14.37 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Saskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.